

Rheumatoid arthritis (update) Committee meeting 5

Date: 07/03/2017

Location: Boardroom, NGC, 180 Great Portland Street, London, W1W 5QZ

Minutes: Confirmed

NICE National Institute for
Health and Care Excellence

Committee members present:		
Stephen Ward (SW, Chair)		(Present for notes 1–5)
Ann Bevan (ABe)		(Present for notes 1–5)
Ailsa Bosworth (ABo)		(Present for notes 1–5)
Vicky Chamberlain (VC)		(Present for notes 1–5)
Amanda Isaac (AI, Co-opted member)		(Present for notes 3–5)
Jennie Jones (JJ)		(Present for notes 1–5)
Bruce Kirkham (BK)		(Present for notes 1–5)
Hilary McKee (HMK)		(Present for notes 1–5)
Frank McKenna (FMK)		(Present for notes 1–5)
Anupama Nandagudi (AN)		(Present for notes 1–5)
Benjamin Parker (BPa)		(Present for notes 4b–5)
Heidi Siddle (HS)		(Present for notes 1–5)
Louise Warburton (LW)		(Present for notes 1–5)

In attendance:		
Alex Allen	Senior Research Fellow, NGC	(Present for notes 1–5)
Serena Carville	Guideline Lead/Associate Director, NGC	(Present for notes 1–5)
Meredith Faust	Document Editor/ Process Assistant, NGC	(Present for notes 1–5)
Sophia Kemmis Betty	Senior Health Economist, NGC	(Present for notes 1–5)
Jacqui Real	Senior Research Fellow, NGC	(Present for notes 1–5)
Grit Scheffler	Research Fellow, NGC	(Present for notes 1–4c)

Apologies:

Caroline Keir	Guideline Commissioning Manager, NICE
Joanne Ashe	Senior Information Scientist, NGC
Ben Pordes	Acting Senior Project Manager, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the fifth meeting on rheumatoid arthritis in adults: diagnosis and management.

No members of the public asked to observe the meeting.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included considering the evidence for poor function and radiological progression risk factors in rheumatoid arthritis, health economic modelling, corticosteroids as bridging treatment and draft protocols.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was poor function and radiological progression risk factors in rheumatoid arthritis, health economics modelling, corticosteroids and draft protocols.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Hilary McKee	Consultant Pharmacist, Antrim Area Hospital	AbbVie sponsored attendance at BSR Birmingham April 2017; AbbVie paid registration fee and accommodation	Personal financial non-specific	Declare and participate
Anupama Nandagudi	Consultant Rheumatologist, Basildon and Thurrock University	IMS– Market research involving attending meetings	Personal financial non-specific	Declare and participate

	Hospital NHS Trust	Market research for Genactis company – Biologic treatment in RA – £160	Personal financial specific	Declare and participate
		Osteoporosis talk to local GPs – Internis	Personal financial non-specific	Declare and participate
		Attended the LEAP meeting- Novartis paid for the meeting, food and travel.	Personal financial non-specific	Declare and participate

The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

4. Presentations and discussion

- a. JR presented the committee with information about reviews of prognostic risk factors.
- b. GS presented the clinical evidence for the risk factors of poor function (HAQ) in rheumatoid arthritis for the review question: In adults with rheumatoid arthritis, which risk factors are associated with poorer long-term function as measured by the Health Assessment Questionnaire (HAQ)? The committee discussed the evidence and drafted recommendations.
- c. JR presented the clinical evidence for the risk factors of radiological progression in rheumatoid arthritis for the review question: In adults with rheumatoid arthritis, which risk factors are associated with worse radiographic progression? The committee discussed the evidence and drafted recommendations.
- d. SKB presented the prioritisation for the modelling of the health economics data in rheumatoid arthritis. The committee discussed the prioritisation.
- e. The committee discussed and agreed the draft protocols for ultrasound for

diagnosis and monitoring.

- f. AA presented the evidence for short-term steroids (remission induction) in rheumatoid arthritis. The committee discussed the evidence.

5. Any other business

None.

Date of next meeting: 21/04/2017

Location of next meeting: Boardroom, National Guideline Centre
180 Great Portland Street
London W1W 5QZ